HomeACC 2021Structural Heart Disease

Structural Heart Disease

ACC 2021 | ATLANTIS 4D-CT: Apixaban and Sub-Clinical Thrombosis After TAVR

Indicating apixaban after transcatheter aortic valve replacement (TAVR) does not significantly reduce the risk of sub-clinical leaflet...

ACC 2021 | ATLANTIS: Apixaban After TAVR vs. Standard of Care

Adding apixaban to the treatment of patients undergoing transcatheter aortic valve replacement (TAVR) was non-superior to standard...

ACC 2021 | LAAOS III: Appendage Closure During Central Vascular Surgery

According to the LAAOS III study, presented at the American College of Cardiology (ACC) 2021 Congress and simultaneously...